



September 15, 2010

## **pSivida Corp Announces Fourth Quarter and Fiscal Year 2010 Financial Results Release Date and Conference Call Information**

WATERTOWN, Mass., Sep 15, 2010 (BUSINESS WIRE) --

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of sustained release drug delivery systems for difficult-to-treat, back-of-the-eye conditions, today announced that its financial results for the fourth quarter and fiscal year 2010 will be released after market close on Wednesday, September 22, 2010, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.

The conference call may be accessed by dialing (866) 730-5764 from the U.S. and Canada, or (857) 350-1588 from international locations, passcode 99650578. A replay of the call will be available approximately two hours following the end of the call through September 29, 2010. The replay may be accessed by dialing (888) 286-8010 within the U.S. and Canada or (617) 801-6888 from international locations, passcode 60197831.

The conference call will be available via the Internet at [www.psivida.com](http://www.psivida.com) and will also be distributed through the Thomson StreetEvents Network. Individual investors can listen to the call via [www.earnings.com](http://www.earnings.com) and Institutional investors can access the call via [www.streetevents.com](http://www.streetevents.com). Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. The call will be archived and accessible on the Web site for approximately 30 days.

### **About pSivida Corp.**

pSivida Corp is a leader in the development of tiny, sustained release, drug delivery products and technologies that are administered by implantation, insertion or injection. The Company uses these systems to develop treatments for serious, unmet, medical needs. pSivida's intellectual property portfolio consists of over 50 patent families, more than 100 granted patents, including patents accepted for issuance, and more than 150 patent applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom.

**SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:** Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: maintaining collaboration agreements with Alimera and Pfizer; modifications of existing terms of collaboration agreements with Alimera and Pfizer; achievement of milestones and other contingent contractual events; ability to prove safety and efficacy of, and achieve regulatory approvals for, and successfully commercialize Iluvien, BrachySil and other products; ability to raise capital; ability to achieve profitability; ability to derive revenues from Retisert; ability to develop new products; impairment of intangibles; fluctuations in the fair values of certain outstanding warrants; fluctuations in operating results; termination of license agreements; ability to obtain partners to develop and market products; competition; extent of third-party reimbursement for products; product liability; ability to protect intellectual property or infringement of others' intellectual property; retention of key personnel; consolidation in the pharmaceutical and biotechnology industries; compliance with laws; maintaining effective internal control over financial reporting; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution through exercise of outstanding warrants and stock options or future stock issuances; possible influence by Pfizer; ability to pay any registration penalties; and other factors described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

For more information on pSivida, visit [www.psivida.com](http://www.psivida.com).

SOURCE: pSivida Corp.

In US:

Martin E. Janis & Company, Inc.

Beverly Jedynek, President

312-943-1123

[bjedynak@janispr.com](mailto:bjedynak@janispr.com)

or

In Australia:

pSivida Corp

Brian Leedman, Vice President, Investor Relations

+61 8 9227 8327

[brianl@psivida.com](mailto:brianl@psivida.com)